Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus concurrent chemoradiotherapy for locally advanced cervical cancer
ChiCTR2000032856Phase 4Recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of tislelizumab, sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Started May 2020; status: recruiting.
02
Drugs
tislelizumab
Beyond the preview
Go deeper on ChiCTR2000032856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032856.